DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

Phase 2

Not yet recruiting

Conditions: Cervical Dystonia

Interventions: Biological: IPN10200
Other: Placebo

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Ipsen

Target Recruit Count: 132

Registration Number: NCT06937931

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy

Interventions: Drug: Palovarotene

First Posted Date: 2025-04-03

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 32

Registration Number: NCT06908954

Locations: 🇺🇸
ERG - Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
American Research Corporation/Texas Liver Institute, San Antonio, Texas, United States

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Recruiting

Conditions: Alagille Syndrome

First Posted Date: 2025-02-27

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 30

Registration Number: NCT06850038

Locations: 🇺🇸
Proactive El Paso,LLC, El Paso, Texas, United States
🇺🇸
NYU Langone - NYU Grossman School of Medicine, New York, New York, United States

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: IPN01195

First Posted Date: 2025-02-18

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 85

Registration Number: NCT06833008

Locations: 🇫🇷
Centre Léon Bérard - Lyon, Lyon, France
🇫🇷
Paris Saint-Louis, Paris, France
🇫🇷
IGR-Villejuif, Villejuif, France

and more 10 locations

A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

Phase 3

Recruiting

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Elafibranor

First Posted Date: 2024-12-12

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 18

Registration Number: NCT06730061

Locations: 🇯🇵
Nippon Medical School - Chiba Hokusoh Hospital, Chiba, Japan
🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇯🇵
Shinshu University Hospital, Nagano, Japan

and more 13 locations

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Phase 2

Recruiting

Conditions: Episodic Migraine
Chronic Migraine

Interventions: Biological: IPN10200
Other: Placebo
Biological: IPN10200 dose B
Biological: IPN10200 dose A

First Posted Date: 2024-10-03

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 641

Registration Number: NCT06625060

Locations: 🇺🇸
Upstate Clinical Research Associates, Williamsville, New York, United States
🇺🇸
Clinical Neuroscience Solutions, Inc - Memphis, Memphis, Tennessee, United States
🇺🇸
Puget Sound Neurology - Neurology, Tacoma, Washington, United States

and more 13 locations

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Recruiting

Conditions: Primary Biliary Cholangitis

First Posted Date: 2024-06-06

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 424

Registration Number: NCT06447168

Locations: 🇦🇹
Medizinische Universitaetsklinik Graz, Graz, Austria
🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪
Hospital of the Merciful Brothers Trier, Trier, Germany

and more 30 locations

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Phase 3

Active, not recruiting

Conditions: Primary Biliary Cholangitis

Interventions: Other: Placebo
Drug: Elafibranor

First Posted Date: 2024-04-25

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 69

Registration Number: NCT06383403

Locations: 🇨🇿
Institute for Clinical and Experimental Medicine - IKEM, Prague, Czechia
🇨🇿
Research Site s.r.o., Plzen, Czechia
🇩🇪
Universitaetsklinikum Muenster, Münster, Germany

and more 57 locations

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Phase 2

Recruiting

Conditions: Osteosarcoma
Osteosarcoma in Children
Osteosarcoma in Adolescents and Young Adults

Interventions: Drug: Cabozantinib
Other: Best Supportive Care (BSC)

First Posted Date: 2024-04-02

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 90

Registration Number: NCT06341712

Locations: 🇩🇪
Klinikum Dortmund, Dortmund, Germany
🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇫🇷
AP-HP Hopital Cochin, Paris, France

and more 71 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Colorectal Cancer
Solid Tumor
Melanoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: IPN01194

First Posted Date: 2024-03-12

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 220

Registration Number: NCT06305247

Locations: 🇫🇷
Centre Léon Bérard - Lyon, Lyon, France
🇫🇷
Paris Saint-Louis, Paris, France
🇺🇸
The Angeles Clinic and Research Institute - California, Los Angeles, California, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy